Tier 4 — mechanistic

Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer's disease mouse model

Le Zhao, Jun-Li Wang, Rui Liu, Xiao-Xu Li, Jian-Fei Li, Lu Zhang
Molecules 2013 18(8):9949-9965

Bibliography

PubMed
PMID 23966081
PubMed Central
PMC6270497
DOI
10.3390/molecules18089949

Study snapshot

DesignIn vivo transgenic mouse study
ModelAPP/PS1 Alzheimer's disease mouse model
Sample
InterventionOral apigenin for three months
Duration3 months
EndpointsLearning and memory; Amyloid-beta burden; ERK/CREB/BDNF signaling; Neurovascular markers

What the study showed, in plain terms

This study tested chronic apigenin treatment in a transgenic mouse model of Alzheimer's disease.

Key findings

Apigenin improved learning and memory measures and altered amyloid and neurotrophic signaling in the mouse model, including ERK/CREB/BDNF-related pathways.

What this study can and cannot tell us

Mouse Alzheimer's models do not establish prevention or treatment of human dementia, and the effective exposure may not translate to supplement use.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology